NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer
- Conditions
- Radiation ToxicityHead and Neck CancerOral Complications of Radiation Therapy
- First Posted Date
- 2004-02-04
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00022373
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Biological: Rituxan (rituximab)Biological: filgrastimOther: immunologic techniqueOther: laboratory biomarker analysisProcedure: autologous hematopoietic stem cell transplantation
- First Posted Date
- 2004-02-03
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT00076752
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccineBiological: recombinant vaccinia-CEA(6D)-TRICOM vaccineBiological: sargramostimOther: laboratory biomarker analysis
- First Posted Date
- 2004-02-03
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT00009958
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States
Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
- First Posted Date
- 2004-02-03
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 748
- Registration Number
- NCT00009906
- Locations
- 🇺🇸
Geisinger Medical Center, Danville, Pennsylvania, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇨🇦Mount Sinai Hospital, Toronto, Ontario, Canada
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome
- Conditions
- Adult Acute Promyelocytic Leukemia (M3)Blastic Phase Chronic Myelogenous LeukemiaPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRefractory Anemia With Excess BlastsRefractory Anemia With Excess Blasts in TransformationRelapsing Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2004-02-02
- Last Posted Date
- 2013-01-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00005064
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2004-01-29
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00004862
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States
Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
- First Posted Date
- 2004-01-27
- Last Posted Date
- 2013-10-16
- Target Recruit Count
- 31
- Registration Number
- NCT00076570
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia
- Conditions
- T-Cell Large Granular Lymphocytic LeukemiaLeukemia, T-Cell Large Granular Lymphocytic
- Interventions
- Biological: Hu-MiK-Beta-1
- First Posted Date
- 2004-01-15
- Last Posted Date
- 2019-01-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT00076180
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2018-04-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00076102
- Locations
- 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸Childrens Hospital, Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸St. Louis Children's Hospital, Saint Louis, Missouri, United States
Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma
- Conditions
- Stage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT00075881
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States